🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

3 Stocks Under $2 Insiders Are Buying

Published 11/05/2022, 13:08
Updated 11/05/2022, 13:40
© Reuters.  3 Stocks Under $2 Insiders Are Buying
CPG
-
IVR
-
TCON
-
IVR_pc
-
I1VZ34
-
CMPX
-
COMP
-

US crude oil futures traded higher on Wednesday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

TRACON Pharmaceuticals

  • The Trade: TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) President and CEO Charles Theuer acquired a total of 2,500 shares at an average price of $1.97. To acquire these shares, it cost $4.92 thousand.
  • What’s Happening: The company is expected to release quarterly earnings after the closing bell today.
  • What TRACON Pharmaceuticals Does: TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States.
Compass Therapeutics
  • The Trade: Compass Therapeutics, Inc. (NASDAQ: CMPX) CEO Thomas J Schuetz acquired a total of 27,836 shares at an average price of $1.80. The insider spent around $50.1 thousand to buy those shares.
  • What’s Happening: Compass Therapeutics posted a Q1 loss of $0.07 per share.
  • What Compass Therapeutics Does: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies.
Also check this: Executives Buy More Than $90M Of 4 Stocks

Don’t forget to check out our premarket coverage here .

Invesco Mortgage Capital

  • The Trade: Invesco Mortgage Capital Inc. (NYSE: IVR) President Kevin Collins acquired a total of 7,178 shares at an average price of $1.67. To acquire these shares, it cost around $11.99 thousand.
  • What’s Happening: The company recently posted upbeat quarterly earnings.
  • What Invesco Mortgage Capital Does: Invesco Mortgage Capital Inc is an REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.